Molecular therapy for Metastatic cancers: Myrtenal, isolated  from Taxus, increases the expression of tumor suppressors BigH3 and TIPE2, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 5/September/2017, 3.33 am

Natural product-based therapy for anxiety and depression: Methyl Jasmonate (JM), isoalted from Jasmine,  increases PHF8 levels, increases the expression of serotonin receptors Htr1a and Htr2a, and promotes resistance to stress-induced -anxiety and -depression via down regulation of its target gene, 4/September/2017, 1.24 am
September 3, 2017
Molecular therapy for Stroke:  Ruxolitinib (brand name: Jakavi), a drug used in the treatment of Myelofibrosis,  attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits via up regulation of its target genes BDNF and NAMPT, 5/September/2017, 3.34 am
September 4, 2017
Show all

From Significance of the study to Public health relevance:

Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them will die; (ii) cancer deaths globally are expected to be doubled by 2030; (iii) most of the cancer patients die due to metastasis; (iv) cancer treatment causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) bio-molecules that drive metastatic process; and the the way to prevent their expression; (ii) a way to activate immune system to combat cancer (Cancer immunotherapy); (ii) a cheaper alternative to the existing expensive anticancer drugs; (ii) a side-effect-free natural product-based drug; (iii) increase the therapeutic index of anticancer drugs; and (iv) a way to effectively treat and prevent metastatic progression and relapse of advanced/drug-resistant cancers.


Research findings to Therapeutic opportunity: 

A number of studies suggests that Myrtenal inhibits tumor cell proliferation. However, the mechanism of action is far from clear.

This study suggests that Myrtenal, by regulating the expression of its target genes, it may increase the expression of  tumor suppressors BigH3 and TIPE2 (fig. 1).

[easy_payment currency=”USD”]

Thereby, it may: (a) inhibit cell cycle progression; and (d) suppress migration, invasion and metastasis of cancer cells. 

Thus,  Myrtenal-based treatment may be advised for metastatic cancer patients to (i) increase the expression of metastasis suppressor genes in tumors; (ii) inhibit the progression of metastatic tumors; and (ii) enhance the efficacy of Cancer therapy. Together, oncologists may consider experimenting the use of Myrtenal in the treatment of advanced metastatic cancers.


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $10#

Undisclosed mechanistic information: How Myrtenal increases the expression of tumor suppressors BigH3 and TIPE2

Fig1. Mechanistic insights into how the natural product-derived compound Myrtenal functions as an anti-metastasis agent. Myrtenal increases the expression of tumor suppressors BigH3 and TIPE2 via down regulation of its target genes.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References: 

CitationBoominathan, L., Molecular therapy for Metastatic cancers: Myrtenal, isolated  from Taxus, increases the expression of tumor suppressors BigH3 and TIPE2, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 5/September/2017, 3.33 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.